One hundred and eleven patients with antiphospholipid antibodies (aPL) were diagnosed at Mie University Hospital during the past 17 years. Two of these patients developed disseminated intravascular coagulation (DIC). The first patient twice developed DIC complicated by pancreatitis and pregnancy, while in the second case, no specific causative complications for DIC were identified. The details of these cases imply that aPL is associated with DIC and/or is a potent triggering factor for DIC.
Introduction
Disseminated intravascular coagulation (DIC) (1) occasionally develops in patients with organ failure. Such patients present with hemostatic abnormalities, including thrombosis and/or bleeding, based on hypercoagulable and hyperfibrinolytic conditions. Antiphospholipid syndrome (APS) is characterized by thrombosis and/or recurrent abortions caused by antiphospholipid antibodies (aPL) (2) . The levels of aPL are not usually measured in patients with DIC. These two diseases sometimes present with similar clinical manifestations, and it is therefore necessary to rule out APS when making a diagnosis of DIC. We herein report two cases of DIC associated with aPL.
Case Reports
One hundred and eleven patients with any type of aPL were evaluated at Mie University Hospital between January 1, 1994 and December 31, 2011. The presence of aPL was diagnosed based on the occurrence of abnormalities in the following laboratory tests; diluted Russell's viper venom time (DRVVT), diluted activated partial thromboplastin time (diluted APTT), anti-cardiolipin antibodies (ACA) and anti-β2 glycoprotein 1-cardiolipin complex antibodies. Seventy of the 111 patients with aPL developed APS and two of these patients developed DIC.
Case 1
A 32-year-old woman who was 29 weeks pregnant was transferred to our hospital complaining of severe abdominal and back pain. Laboratory examinations (Table) revealed elevated serum amylase levels (331 IU/L), thrombocytopenia (33,000/μL) and prolonged APTT (49.5 seconds). The patient had a history of pancreatitis at age 14, and she underwent minor papillectomy at 26 years of age at our hospital. She was diagnosed as having relapsed pancreatitis and was treated with urinastatin (75,000 U/day) and cefodizime (2 g/ day). Her amylase level decreased and her abdominal pain disappeared following treatment. The fibrin and fibrinogen degradation products (FDP) level was elevated at 34.9 μg/ mL, the platelet count was decreased at 2.2×10 4 /μL and the DIC score was five points. She was diagnosed as having an overt-DIC condition based on the International Society of Thrombosis and Haemostasis (ISTH) overt-DIC criteria (3). She was treated with a combination of gabexate mesilate (2,000 mg/day), danaparoid sodium (2,500 anti-Xa units/ day) and antithrombin (1,500 U/day). She responded to the therapy, and her platelet count and FDP levels partially re-covered. As described in Fig. 1 , she was also diagnosed with APS according to the Sapporo criteria due to the pres- APTT: activated partial thromboplastin time, FDP: fibrinogen/fibrin Degradation products, PIC: plasmin-lasmin inhibitor complex, GOT: glutamic-oxaloacetic transaminase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, T-Bil: total bilirubin, T-chol: total cholesterol, CPK: creatine phosphokinase, CRP: C-reactive protein ence of anticardiolipin antibodies and lupus anticoagulant, and she subsequently developed DIC (4) . High levels of anti-Sjögren's syndrome-A/Sjögren's syndrome-B antibodies specific for Sjögren's syndrome were detected in the patient's sera. Therefore, she was treated for APS with oral prednisolone at 10 mg/day. On day 19, the fetal heartbeat became weak. Fortunately, the patient's hemostatic conditions had normalized, and she underwent cesarean section. She delivered a healthy infant without experiencing any specific complications, including bleeding or thrombosis. She experienced a second pregnancy without developing any symptoms of pancreatitis one year after the first delivery. Her pregnancy was complicated by DIC starting at 20 weeks gestation. Therefore, she was treated with low-dose heparin, low-dose aspirin and 20 mg/day of oral prednisolone. Her hemostatic abnormalities improved, and she delivered the second infant without complications, including bleeding or thrombosis.
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Case 2
A 51-year-old woman presented at our hospital complaining of numerous petechiae on her extremities without any systemic symptoms. A laboratory examination revealed a decreased platelet count at 36,000/μL (Table) . The patient was followed without the administration of any treatment. She underwent hysterectomy and bilateral oophorectomy for endometriosis at 45 years of age. Two years later, she developed numerous large purpuras. Her platelet count was decreased at 2.4×10 4 /μL and her FDP level was elevated at 70.0 μg/mL. Her DIC score was five points. She was diagnosed with DIC and admitted to our hospital. She was treated with an infusion of platelet concentrate, gabexate mesilate (2,000 mg/day) and danaparoid sodium (2,500 anti-Xa units/day), as shown in Fig. 2 . She was also diagnosed with APS based on a high LA test and the presence of anticardiolipin antibodies. She was treated with 3 mg/day of warfarin, 80 mg/day of aspirin and 15 mg/day of prednisolone without gabexate mesilate or danaparoid sodium to return the FDP, fibrinogen and platelet counts to the normal levels. Her hemostatic abnormalities also improved.
Discussion
The presence of pathogenic aPL is characteristic for APS. Affected patients develop recurrent pregnancy loss and thrombosis (5). Asherson first described catastrophic APS, a severe variant of APS characterized by DIC that resuls in multiorgan failure (6) . Manifestations of DIC were identified in 23 (13%) of 173 patients with catastrophic APS (7) . This implies that DIC features are not rare in patients with catastrophic APS. Screening for aPL is required in patients with DIC without specific precipitating factors. The pathogenesis of DIC and catastrophic APS is poorly understood. However, these two conditions may have common pathogenic mechanisms and/or triggering factors.
In Case 1, acute pancreatitis might have triggered DIC. However, the DIC conditions persisted after the pancreatitis improved. Both aPL and pregnancy might have enhanced hypercoagulability in this case. The patient did not have pancreatitis during her second pregnancy; however, the pregnancy was again complicated by DIC. In addition, aPL and pregnancy might have further enhanced the patient's hypercoagulability. Elevations in the tissue factor levels that trigger the extrinsic coagulation pathway have been reported in systemic lupus erythematosus patients with aPL (8) . The occurrence of intracellular signal transduction triggered by aPL has been investigated, and the p38 mitogen activated protein kinase pathway has been revealed to be a major player in aPL-mediated cell activation (9) .
In Case 2, no obvious causative factors for DIC were identified. The hemostatic abnormalities in both cases improved after the administration of systemic corticosteroid therapy, which is an effective therapy for APS. Neither of the patients presented with apparent organ involvement, in-cluding venous thromboemboli, stroke, acute myocardial infarction or abortion. However, they developed DIC and microthrombosis with the presence of aPL. The details of the present two cases revealed that DIC is occasionally complicated by aPL and/or that aPL is a potent causative factor for DIC.
Although these cases were not diagnosed as APS according to the diagnostic criteria proposed by Sydney (10), the administration of steroid therapy was effective and DIC was associated with laboratory thrombosis in both cases, suggesting that the cases might be diagnosed as APS. Catastrophic APS is treated with plasmapheresis, steroid pulse therapy or other intensive treatments; however, these cases were of the mild and chronic type.
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